12:00 AM
 | 
Oct 16, 2006
 |  BioCentury  |  Emerging Company Profile

Codexis: Breeding a product story

Armed with a recent series D financing, Codexis Inc. says it is ready to make the transition from a technology platform-based company to a fully-fledged product development story. The synthetic chemistry company will now use its MolecularBreeding technology to develop generic products in-house, expanding beyond licensing the technology to pharmaceutical and generics companies.

"Four years ago, our technology was a science. We then reduced it to a technology, and now we are applying it to maximize the value of our investment," said CEO Alan Shaw. "The financing marks a milestone in the company's evolution to becoming a significant player...

Read the full 476 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >